Related Experiment Video
Updated: May 21, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy
Ning Li1, Chunhua Zhang2, Xiaoyu Li3
1Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa 999078, Macao.
Abstract:
Ovarian and gastric cancers, representative of many solid tumors, remain among the most challenging malignancies to treat due to limited therapeutic options and poor outcomes at advanced stages. Although immunotherapies have revolutionized cancer treatment, their efficacy in solid tumors has been hindered by issues such as antigen heterogeneity and the immunosuppressive tumor microenvironment. This study presents the development and evaluation of third-generation chimeric antigen receptor T (CAR-T) cells targeting B7-H3, an immune checkpoint molecule widely overexpressed in solid tumors. The B7-H3 CAR-T cells exhibited robust and selective cytotoxicity against B7-H3-positive tumor cells, sparing normal tissues. In preclinical animal models, these cells significantly inhibited tumor growth, demonstrating higher targeting specificity and preferential accumulation in tumor sites. These results highlight B7-H3-targeted CAR-T cells as a potential breakthrough in immunotherapy for solid tumors, offering a foundation for future clinical trials to refine their safety and efficacy.
Insights
New chimeric antigen receptor T (CAR-T) cells targeting B7-H3 show promise for treating solid tumors like ovarian and gastric cancers. These engineered immune cells effectively kill cancer cells while sparing normal tissues in preclinical studies.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Solid tumors, including ovarian and gastric cancers, present significant treatment challenges.
- Current immunotherapies face limitations in solid tumors due to antigen heterogeneity and immunosuppressive microenvironments.
Purpose of the Study:
- To develop and evaluate third-generation chimeric antigen receptor T (CAR-T) cells targeting B7-H3.
- To assess the efficacy and specificity of B7-H3 CAR-T cells against solid tumors.
Main Methods:
- Development of third-generation CAR-T cells engineered to target the B7-H3 immune checkpoint molecule.
- In vitro assessment of CAR-T cell cytotoxicity against B7-H3-positive tumor cells.
- In vivo evaluation of B7-H3 CAR-T cell anti-tumor activity and biodistribution in preclinical animal models.
Main Results:
- B7-H3 CAR-T cells demonstrated potent and selective killing of B7-H3-positive tumor cells, with minimal impact on normal tissues.
- Preclinical models showed significant inhibition of tumor growth mediated by B7-H3 CAR-T cells.
- These cells exhibited enhanced tumor targeting specificity and preferential accumulation at tumor sites.
Conclusions:
- Third-generation B7-H3 CAR-T cells represent a promising immunotherapy strategy for solid tumors.
- These findings provide a strong rationale for further clinical investigation of B7-H3-targeted CAR-T cell therapy.
